Andy Sassine Net Worth

The estimated Net Worth of Andy Sassine is at least $3.54 Million dollars as of 12 June 2024. Andy Sassine owns over 50,000 units of Exicure Inc stock worth over $341,815 and over the last 9 years Andy sold XCUR stock worth over $3,196,300.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Andy Sassine XCUR stock SEC Form 4 insiders trading

Andy has made over 14 trades of the Exicure Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Andy sold 50,000 units of XCUR stock worth $1,601,500 on 12 June 2024.

The largest trade Andy's ever made was selling 50,000 units of Exicure Inc stock on 12 June 2024 worth over $1,601,500. On average, Andy trades about 4,418 units every 30 days since 2015. As of 12 June 2024 Andy still owns at least 220,526 units of Exicure Inc stock.

You can see the complete history of Andy Sassine stock trades at the bottom of the page.

What's Andy Sassine's mailing address?

Andy's mailing address filed with the SEC is C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA, NH, 03062.

Insiders trading at Exicure Inc

Over the last 6 years, insiders at Exicure Inc have traded over $4,850,172 worth of Exicure Inc stock and bought 7,217,940 units worth $10,705,021 . The most active insiders traders include Timothy P Walbert, Co., Ltd. Dgp, and Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of $928,360. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth $4,488,000.

What does Exicure Inc do?

exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.

Complete history of Andy Sassine stock trades at Icad Inc, Arcturus Therapeutics Inc, and Exicure Inc

Exicure Inc executives and stock owners

Exicure Inc executives and other stock owners filed with the SEC include:

• David Giljohann,
  Chief Executive Officer, Interim Principal Financial Officer, Corporate Secretary, Director
• Matthias Schroff,
  Chief Operating Officer
• Dr. Douglas E. Feltner,
  Chief Medical Officer
• Chad Mirkin,
  Director
• Bali Muralidhar,
  Independent Director
• Bosun Hau,
  Independent Director
• Jay Venkatesan,
  Independent Director
• Helen Kim,
  Independent Director
• Timothy Walbert,
  Independent Chairman of the Board
• David Walt,
  Independent Director
• Jeffrey Cleland,
  Independent Director
• Karen Sharma,
  Investor Relations
• Bart Anderson,
  Sr. Director of R&D
• Dr. Emil M. deGoma M.D.,
  VP of Clinical Devel.
• Weston Daniel,
  VP of Translational Research
• Sarah Longoria,
  VP of HR
• Christoph Jaeker,
  VP of Corp. Devel. & Strategy
• Elias D. Papadimas,
  Chief Accounting Officer
• Brian C. Bock,
  Chief Financial Officer
• Elizabeth A. Garofalo,
  Director
• Andy Sassine,
  Director
• Llc Aurasense,
  10% owner
• Douglas E. Feltner,
  Chief Medical Officer
• James R Sulat,
  Director
• Colby Shad Thaxton,
  Director
• David S Snyder,
  Chief Financial Officer
• Frontier, Llcgates William ...,
  
• Brian Bock,
  Chief Financial Officer
• Co., Ltd. Dgp,
  
• Elias D. Papadimas,
  Chief Financial Officer
• Sarah Longoria,
  Chief HR & Compliance Officer
• Usa, Inc. Cbi,
  
• Jiyoung Hwang,
  Director
• Josh Miller,
  Chief Accounting Officer